Aryl substituted cyclic amines as selective dopamine d3 ligands

Details Aryl substituted cyclic amines as selective dopamine d3 ligands Aryl substituted cyclic amines as selective dopamine d3 ligands

C - Chemistry, Metallurgy

07

C

C07C 311/18 (2006.01) A61K 31/16 (2006.01) A61K 31/18 (2006.01) A61K 31/19 (2006.01) A61K 31/255 (2006.01) A61K 31/275 (2006.01) A61K 31/40 (2006.01) A61K 31/415 (2006.01) A61K 31/435 (2006.01) A61K 31/50 (2006.01) C07C 233/78 (2006.01) C07C 235/84 (2006.01) C07C 237/48 (2006.01) C07C 255/57 (2006.01) C07C 275/32 (2006.01) C07C 275/40 (2006.01) C07C 309/65 (2006.01) C07C 311/05 (2006.01) C07C 311/19 (2006.01) C07C 311/38 (2006.01) C07D 209/70 (2006.01) C07D 215/38 (2006.01) C07D 221/04 (2006.01) C07D 233/84

Patent

CA 2255612

Compounds and their pharmaceutically acceptable salts suitable for treating central nervous system disorders associated with the dopamine D3 receptor activity of structural Formula (I) where X and Y are at the 5, 6, or 7 position wherein i) n is 1 then X is (CH2)mCONR4R5, (CH2)mSO2R3, (CH2)mSO2NR4R5, (CH2)mNR4CONHR5, (CH2)mNHSO2R3, (CH2)mNHCOR3, or C(O)R4 (where m is 0 or 1, except that where m is 0, the Y is not hydrogen or halogen); and Y is R4, (CH2)pCONR4R5, (CH2)pCN, (CH2)pSO2NR4R5, OR6, (CH2)pSO2R3, (CH2)pNHSO2R3, halogen or (CH2)pNHCOR3 (where p is 0 or 1); ii) n is 0 or 1 then X and Y are in ortho-positions relative to each other and are jointly: a) -C(O)NR10C(O)-, b) -C(O)NR4(CH2)xNR10C(O)- (where x is 0 or 1), c) - CH2NR10C(O)-, d) -(CH2)2NR10C(O)-, e) -CH2C(O)NR10-, f) -N(R3)-C(O)-N(R3)-, g) -N(R3)-C(O)-O-, h) -N=C(R7)-N(R3)-, or j) -CH2N(R8)CH2-; or iii) n is 0 and Y is OR9 then X is (CH2)mCONR4R5, (CH2)mSO2NR4R5, (CH2)mNR4CONHR5, (CH2)mSO2R3, (CH2)mNHSO2R3 or (CH2)mNHCOR3, C(O)R4 (where m is 0 or 1). A compound of structural Formula (II) or its pharmaceutically acceptable salts where one of A, B, C, or D is nitrogen and remaining positions are CH; n is 1 or 2; X and Y are: i) substituted at positions A, B, C, or D wherein X is (CH2)mCONR4R5, (CH2)mCN, (CH2)mSO2NR4R5, OSO2R3, (CH2)mNR4CONHR5, (CH2)mSO2R3, (CH2)mNHSO2R3 or (CH2)mNHCOR3, C(O)R4 (where m is 0 or 1, except that where m is 0, Y is not hydrogen or halogen); and Y is R4, (CH2)pCONR4R5, (CH2)pCN, (CH2)pSO2NR4R5, OR6, OSO2R3, (CH2)pSO2R3, (CH2)pNHSO2R3, halogen or (CH2)pNHCOR3 (where p is 0 or 1); or ii) jointly in an ortho-positions relative to each other and are: - C(O)NR4C(O)-, -CH2NR4C(O)-, -CH2C(O)NR4- or -CH2N(R4)CH2-. A compound of structural Formula (III) or its pharmaceutically acceptable salts wherein one of E or F is N and the other is S; n is 1 or 2. The R1-10 groups for structural Formula (I), (II) and (III) are as defined above.

L'invention concerne des composés et leurs sels pharmaceutiquement acceptables de formule I, appropriés au traitement de troubles du système nerveux central associés à l'activité du récepteur de la dopamine D3. Dans ladite formule (I), X et Y se trouve en position 5, 6 ou 7 où i) n vaut 1 alors X représente (CH2)¿m?CONR¿4?R¿5?, (CH¿2?)¿m?SO¿2?R¿3?, (CH¿2?)¿m?SO¿2?NR¿4?R¿5?, (CH¿2?)¿m?NR¿4?CONHR¿5?, (CH¿2?)¿m?NHSO¿2?R¿3?, (CH¿2?)¿m?NHCOR¿3? ou C(O)R¿4? (où m vaut 0 ou 1, sauf que lorsque m vaut 0, Y ne représente ni hydrogène ni halogène); et Y représente R¿4?, (CH¿2?)¿p?CONR¿4?R¿5?, (CH¿2?)¿p?CN, (CH¿2?)¿p?SO¿2?NR¿4?R¿5?, OR¿6?, (CH¿2?)¿p?SO¿2?R¿3?, (CH¿2?)¿p?NHSO¿2?R¿3?, halogène ou (CH¿2?)¿p?NHCOR¿3? (où p vaut 0 ou 1); ii) n vaut 0 ou 1 alors X et Y sont en position ortho l'un par rapport à l'autre et sont conjointement: a) -C(O)NR¿10?C(O)-, b) C(O)NR¿4?(CH¿2?)¿x?NR¿10?C(O)- (où x vaut ou 1), c) -CH¿2?NR¿10?C(O)-, d) - (CH¿2?)¿2?NR¿10?C(O)-, e) -CH¿2?C(O)NR¿10?-, f) -N(R¿3?)-C(O)-N(R¿3?)-, g) -N(R¿3?)-C(O)-O-, h) -N=C(R¿7?)-N(R¿3?)-, ou j) -CH¿2?N(R¿8?)CH¿2?-; ou iii) n vaut 0 alors Y représente OR¿9? et X est donc (CH¿2?)¿m?CONR¿4?R¿5?, (CH¿2?)¿m?SO¿2?NR¿4?R¿5?, (CH¿2?)¿m?NR¿4?CONHR¿5?, (CH¿2?)¿m?SO¿2?R¿3?, (CH¿2?)¿m?NHSO¿2?R¿3? ou (CH¿2?)¿m?NHCOR¿3?, C(O)R¿4? (où m vaut 0 ou 1). L'invention se rapporte aussi à un composé de formule structurale II ou à ses sels pharmaceutiquement acceptables, où A, B, C ou D représente azote et les positions restantes sont CH; n vaut 1 ou 2; X et Y sont: i) substitués en position A, B, C ou D, X étant (CH¿2?)¿m?CONR¿4?R¿5?, (CH¿2?)¿m?CN, (CH¿2?)¿m?SO¿2?NR¿4?R¿5?, OSO¿2?R¿3?, (CH¿2?)¿m?NR¿4?CONHR¿5?, (CH¿2?)¿m?SO¿2?R¿3?, (CH¿2?)¿m?NHSO¿2?R¿3? ou (CH¿2?)¿m?NHCOR¿3?, C(O)R¿4? (où m vaut 0 ou 1, excepté que lorsque m vaut 0, Y n'est pas ni hydrogène ni halogène); et Y est R¿4?, (CH¿2?)¿p?CONR¿4?R¿5?, (CH¿2?)¿p?CN, (CH¿2?)¿p?SO¿2?NR¿4?R¿5?, OR¿6?, OSO¿2?R¿3?, (CH¿2?)¿p?SO¿2?R¿3?, (CH¿2?)¿p?NHSO¿2?R¿3?, halogène ou (CH¿2?)¿p?NHCOR¿3? (où p vaut 0 ou 1); ou conjointement en positions ortho l'un par rapport à l'autre: -C(O)NR¿4?C(O)-, -CH¿2?NR¿4?C(O)-, -CH¿2?C(O)NR¿4?- ou -CH¿2?N(R¿4?)CH¿2?-. Elle concerne aussi un composé de formule structurale III ou ses sels pharmaceutiquement acceptables, où E ou F est N et l'autre est S; n vaut 1 ou 2. Les groupes R¿1-10? pour la formule structurale I, II et III sont définis ci-dessus.¿ ?

Affiliated with

Also associated with

Rating

Aryl substituted cyclic amines as selective dopamine d3 ligands does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl substituted cyclic amines as selective dopamine d3 ligands, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl substituted cyclic amines as selective dopamine d3 ligands will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFCA-PAI-O-1474776